The influence of estradiole and tibolone administration on leptin levels in women with surgically induced menopause.
BACKGROUND
Several studies suggest that changes in estrogens and androgens during menopause play a role in the regulation of leptin production. Some authors present hypothesis that sex hormone replacement therapy can modulate leptin levels but up to date evidence shows that the influence of endogenous estrogens, androgens levels and sex hormone therapy on leptin concentration remains uncertain.


OBJECTIVE
To evaluate the influence of surgically induced menopause on serum leptin levels and the influence of different types of hormonal therapy on serum leptin concentrations.


METHODS
58 women with surgically induced menopause were divided into three groups. Women who did not receive any hormonal substitution (group 1), women who received Estradiol l mg per day (group 2) and women who received Tibolone 2,5 mg per day (group 3). The levels of leptin, estradiol, testosterone, testosterone, dehydroepiandrosterone sulfate, FSH, LH and progesterone were measured in all subjects on the 5th day and after 3 months following the surgical procedure.


RESULTS
Mean serum leptin concentrations did not differ statistically in any of the studied groups in the beginning and in the end of the study. There was no correlations between serum leptin and estradiol, LH, FSH, progesterone, testosterone, free testosterone and DHEAS concentrations in any of groups before and after treatment.


CONCLUSIONS
Changes in sex hormone concentrations caused by ovariectomy do not influence serum leptin concentrations. Also the short term administration of low dose estrogen therapy or tibolone in postmenopausal subjects does not change serum leptin levels.
Petzel
Martin
M
Department of Obsteric and Gynecology, University Hospital Ostrava Poruba, Czech Republic. M.Petzel@seznam.cz
Stejskal
David
D
Jedelsky
Libor
L
Kadalova
Lenka
L
Safarcik
Kristian
K
D000328:Adult; D004958:Estradiol / Q000627:therapeutic use*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D020738:Leptin / Q000097:blood*; D008594:Menopause, Premature / Q000097:blood*; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D010052:Ovariectomy / Q000009:adverse effects*
D020847:Estrogen Receptor Modulators; D020738:Leptin; D009652:Norpregnenes; D004958:Estradiol; C027385:tibolone